Discovery of a first in class oral anti-inflammatory drug for eczema

湿疹是最常见的炎症性皮肤病，影响15-20%的儿童和高达10%的成人，发病率很高。这是一种慢性复发性疾病，疾病发作的频率和持续时间各不相同，其中瘙痒、抓挠和感染症状加剧。近年来，很少有口服小分子药物获批用于湿疹，由于缺乏疗效、副作用或给药途径，目前的治疗方案不是最佳的。In4Derm已经发现了一种治疗湿疹的新方法，我们相信它将提供甲氨蝶呤的好处，而没有副作用。我们将在小鼠和人类细胞和组织中发现并验证炎症性疾病的生物标志物模型，这些模型可用于预测动物疾病模型和临床试验中的药物效应。这将增加药物成功进入市场的机会。

Eczema is the most common inflammatory skin disease, affecting 15-20% of children and up to 10% of adults, associated with substantial morbidity. It is a chronic relapsing condition, with varying frequency and duration of disease flares, in which the symptoms of itching, scratching and infection intensify. There have been few oral small molecule drug approvals for eczema in recent years, and current treatment options are sub-optimal due to lack of efficacy, side effects or route of administration. In4Derm has discovered a novel approach to the treatment of eczema that we believe will deliver the benefits of methotrexate, without the side effects. We will discover and validate biomarker models of inflammatory disease in mouse and human cells and tissues that can be used to predict drug effects in animal models of disease and in clinical trials. This will increase the chance of a drug successfully reaching the market.